Last reviewed · How we verify
NCT05154721
Rhythm Training of a Serious Game on the Reading Skills of Children w/ a Specific Learning Disorder Impacting Reading
NA trial testing experimental Group - Mila-Learn in Learning Disorder, Specific in 151 participants. Completed in 3 April 2023.
3 April 2023
Quick facts
| Lead sponsor | Poppins |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 151 |
| Start date | 1 October 2021 |
| Primary completion | 3 April 2023 |
| Estimated completion | 3 April 2023 |
| Sites | 3 locations across France |
Drugs / interventions tested
- experimental Group - Mila-Learn
- control Group - Mila-Placebo
Conditions studied
- Learning Disorder, Specific — all drugs for Learning Disorder, Specific →
- Learning Disabilities — all drugs for Learning Disabilities →
- Dyslexia — all drugs for Dyslexia →
- Specific Learning Disorder, With Impairment in Reading — all drugs for Specific Learning Disorder, With Impairment in Reading →
Sponsor
Poppins
Who can join
Adults 7 to 11, any sex, with Learning Disorder, Specific or Learning Disabilities. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mila-Learn-01 is a double-blind clinical study (meaning that neither the patient nor the doctor or his/her team will know which game the child has), which enables us to see the effect of a serious game on the child's reading skills. The patients who will participate in this research will receive, at random, one of the two serious study games, the experimental game (Mila-Learn) or the placebo game (Mila-Placebo). The tasks designed in the placebo game mirror those of Mila-Learn. Each game comprises eight tasks to be completed on a touchscreen tablet. Each session lasts 25 minutes (±20%); five training sessions lasting 25 minutes are planned per week for eight weeks.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Serious Game to Train Rhythmic Abilities in Children With Dyslexia: Feasibility and Usability Study.
Vonthron F, Yuen A, Pellerin H, Cohen D, et al · · 2024 · cited 4× · PMID 37830510 · DOI 10.2196/42733 -
Rhythm training improves word-reading in children with dyslexia.
Descamps M, Grossard C, Pellerin H, Lechevalier C, et al · · 2025 · cited 2× · PMID 40399331 · DOI 10.1038/s41598-025-02485-y
Verify or expand the search:
- PubMed search for NCT05154721
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Learning Disorder, Specific
Currently open trials in the same condition.
- NCT06902610 — Examining the Medium-term Effect on Non Inferiority of the Previous Training With the DMD Poppins Clinical for Cognitive · recruiting
Other Poppins trials
Trials by the same sponsor.
- NCT06902610 — Examining the Medium-term Effect on Non Inferiority of the Previous Training With the DMD Poppins Clinical for Cognitive · recruiting
- NCT06592911 — Examining the Effect of a Digital MD for Cognitive and Musical Training + Reduced Conventional SOC on the Reading and Wr · NA · completed
- NCT06596980 — Examining the Effect of a Digital Medical Device for Cognitive and Musical Training in Children With Reading Disabilitie · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05154721 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poppins
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05154721.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing